Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
RESEARCH TOOLSreports
Holding OTLK?
Track your performance easily
Earnings Data
Report Date
Feb 18, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.88Last Year’s EPS
-0.8Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Dec 18, 2018
|% Change Since: 28.82%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in regulatory approvals and clinical trials, along with a strong financial position. However, there were delays in the BLA resubmission timeline and increased expenses. Overall, the positive developments and strategic advancements outweigh the challenges noted.Company Guidance
During the Q3 2024 earnings call, Outlook Therapeutics provided several key updates and guidance metrics. The company announced it has received marketing authorization for its ophthalmic formulation of bevacizumab in the European Union and the United Kingdom. They are preparing for commercial launch in these regions in the first half of 2025, with ongoing market access work and inventory planning. In the United States, the NORSE EIGHT clinical trial is progressing, with 359 of the planned 400 subjects enrolled, and completion expected by the end of Q3 2024. Outlook Therapeutics anticipates top-line results from NORSE EIGHT in Q4 2024 and plans to resubmit the Biologics License Application (BLA) to the FDA in Q1 2025. Financially, the company reported a reduction in adjusted net loss and R&D expenses from the previous quarter, with a cash position of $32 million as of June 30, 2024, and expected proceeds of $107 million from the exercise of warrants, supporting operations through 2025.Regulatory Approvals in the EU and UK
Outlook Therapeutics received marketing authorization for an ophthalmic formulation of bevacizumab for the treatment of retina diseases in the European Union and the United Kingdom.
NORSE EIGHT Clinical Trial Progress
NORSE EIGHT clinical trial in the U.S. is progressing well with 359 of the planned 400 subjects enrolled, with expected enrollment completion before the end of the third quarter.
Positive FDA Interactions
Completed Type C and D meetings with the FDA addressing open CMC items, indicating positive discussions and progress towards resubmitting the BLA in Q1 2025.
Strong Financial Position
Cash position of $32 million and expected $107 million from the exercise of warrants should support operations through calendar 2025.
Reduction in Convertible Notes
Outstanding convertible notes reduced to approximately $30.3 million, indicating improved financial health.
---
OTLK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OTLK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Dec 27, 2024 | $1.70 | $2.01 | +18.24% |
| Aug 14, 2024 | $7.75 | $7.34 | -5.29% |
| May 15, 2024 | $7.43 | $7.33 | -1.35% |
| Feb 14, 2024 | $8.00 | $8.41 | +5.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Outlook Therapeutics (OTLK) report earnings?
Outlook Therapeutics (OTLK) is schdueled to report earning on Feb 18, 2025, TBA Not Confirmed.
What is Outlook Therapeutics (OTLK) earnings time?
Outlook Therapeutics (OTLK) earnings time is at Feb 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OTLK EPS forecast?
OTLK EPS forecast for the fiscal quarter 2025 (Q1) is -0.88.
---